ARA-290
Case StudyThe peptide community's accumulated experience with ARA-290 centres on practical questions: what does the first cycle feel like, what's the right dose, what does it stack with, what's the non-response rate, what's the lot-to-lot variability look like? The honest pattern: 4 mg 1x daily subq produces modal response in roughly 70-80% of users with the remainder showing partial or absent response.
Key Takeaways
Community lens: aggregated reports on ARA-290 converge on incremental rather than dramatic effects over 4-8 weeks. Mechanism: Selectively activates the innate repair receptor (β-common-receptor / EPOR heteromer) on injured tissue. Reported non-response rate: 15-25% of users describe absent or partial response at 4 mg 1x daily subq dosing. Community dose-range convergence: research-dose range produces modal response; substantial upward adjustment produces diminishing returns. Community-favoured stack partners: BPC-157, TB-500, Ipamorelin.
Community-reported mechanism narratives for ARA-290: how users describe what the compound feels like, what the dosing convergence looks like across thousands of reports, which stacking patterns work, and what fraction of users fall outside the modal experience. Selectively activates the innate repair receptor (β-common-receptor / EPOR heteromer) on injured tissue. Reduces inflammatory cytokine release and supports nerve and tissue repair. Critically, it does not bind the homodimeric EPOR responsible for erythropoiesis. The four subsections below summarise.
Stacking patterns and community wisdom
The most-reported ARA-290 stack combinations rotate through Cibinetide, Pyroglutamate helix B peptide and the canonical pairings appropriate to its mechanism. Community convergence on these patterns is one of the most useful signals for new users — not because the community is always right, but because the well-tolerated combinations have been filtered over many cycles.
What works and what doesn't
Honesty about non-response is one of the more useful contributions of community reporting. Roughly 15–25% of users report that ARA-290 did not produce the expected effect for their specific use case. The most-cited reasons: dose timing relative to food, vendor quality issues, expectations calibrated to dramatic stories rather than the actual modest profile, and stacking complexity that masked the individual contribution.
Common dosing diary patterns
User dosing diaries converge on 4 mg as the standard, with experienced users sometimes adjusting upward by 25–50% and reporting diminishing returns thereafter. The diary patterns also show that subcutaneous administration is the dominant route, and that consistency matters more than absolute dose.
Side Effect Reports is one of the more-reported community use cases for ARA-290. The aggregate experience pattern: most users report incremental benefit within 4–8 weeks, a minority report no response, and dramatic responses are rare. Setting expectations to the modal experience improves user satisfaction.
Community dosing diaries for ARA-290 in stack combinations tried converge on consistent dosing patterns. The shared wisdom is more useful than any individual report — not because the community is always right but because consistent patterns across many users filter idiosyncratic experiences.
For subjective effect timeline, community first-cycle reports on ARA-290 tend to undersell the response, while second-cycle reports tend to oversell. The honest middle is what experienced users describe — modest, consistent, and worth the protocol effort for users with baseline-appropriate indications.
Onset & Duration is one of the more-reported community use cases for ARA-290. The aggregate experience pattern: most users report incremental benefit within 4–8 weeks, a minority report no response, and dramatic responses are rare. Setting expectations to the modal experience improves user satisfaction.
| Goal | Route | Dose | Cycle |
|---|---|---|---|
| Standard protocol | SubQ | 4 mg | 8–12 weeks on / 4 weeks off |
| Conservative starter | SubQ | 2 mg | 4–6 weeks initial cycle |
| Case Study focus | SubQ | 4 mg | 1x daily SubQ |
| Maintenance phase | SubQ | 3 mg | Ongoing with periodic pauses |
Dose timing for ARA-290 is important relative to food and training given the short half-life. Consistency through the cycle is more important than the precise clock time of individual doses.
ARA-290 stacks well with compounds on complementary pathways. The pairings below are the conventional combinations from the experienced peptide community.
- ARA-290 + BPC-157: Upregulates VEGFR2 to promote angiogenesis and activates the FAK-paxillin pathway for accelerated tissue repair. Pairs naturally with ARA-290's mechanism in first-person / case studies protocols.
- ARA-290 + TB-500: Binds G-actin monomers and prevents their incorporation into F-actin filaments, regulating the cellular actin pool. Pairs naturally with ARA-290's mechanism in first-person / case studies protocols.
- ARA-290 + Ipamorelin: Highly selective GHSR1a agonist. Pairs naturally with ARA-290's mechanism in first-person / case studies protocols.
- ARA-290 + GHK-Cu: GHK chelates copper(II) and acts as a transcriptional modulator: published microarray data show it influences over 4,000 human genes including resetting expression patterns toward younger cellular phenotypes. Pairs naturally with ARA-290's mechanism in first-person / case studies protocols.
Excellent tolerability in published trials. Does not raise hemoglobin. Watch for rare injection site reactions.
Lens-specific safety considerations for first-person / case studies use of ARA-290: Excellent tolerability in published trials. Does not raise hemoglobin. Watch for rare injection site reactions. Additional first-person / case studies monitoring at baseline and 6–8 week follow-up is appropriate.
| Compound | Profile | Onset | Best For |
|---|---|---|---|
| ARA-290 | EPO-derived tissue-protective peptide | ~2 min plasma; long tissue effect | Case Study |
| BPC-157 | Stable gastric pentadecapeptide | ~4 hr (oral) | Accelerated tendon, ligament, and gut tissue repair via VEGFR2-driven angiogenesis and FAK-paxillin signalling |
| TB-500 | Synthetic thymosin β4 fragment | ~2-3 days | A 17-amino-acid synthetic fragment of thymosin β4 with actin-sequestering activity — drives cell migration, tissue repair, and broad regenerative effects |
| GHK-Cu | Tripeptide-copper complex | ~30 min plasma | A naturally occurring tripeptide-copper complex that declines with age and is studied for its broad effects on wound healing, skin remodelling, and gene expression |
| Ipamorelin | Selective GHRP / ghrelin mimetic | ~2 hr | The most selective ghrelin-receptor agonist among the GHRPs — stimulates GH release with minimal effect on cortisol, prolactin, or appetite |
Side effects users actually report?
Common mistakes new users make?
Is ARA-290 a good first peptide?
Best practice for storage and travel?
What does ARA-290 stack well with?
What are the safety considerations for ARA-290?
Start a ARA-290 Protocol
Alukard provides physician-supervised protocols with GMP-certified ARA-290 and GMP-certified compounds dispensed with personalised dosing protocols.
Get ProtocolQuick Facts
- Molecular weight
- 1257 Da
- Sequence length
- 11 aa
- Half-life
- ~2 min plasma; long tissue effect
- WADA
- Not specifically listed (EPO analogues require care)
- FDA
- Unapproved (Phase II/III in sarcoidosis & neuropathy)
- Research
- Multiple Phase II human trials
Stack Partners
All first-person / case studies applications described on this page are derived from preclinical research, animal models, and limited human case data. None of these uses are FDA-approved indications for ARA-290 unless otherwise noted. Always work with a physician familiar with peptide therapeutics before beginning a protocol.
Start Your First-Person / Case Studies Protocol for ARA-290
Alukard provides physician-supervised protocols with GMP-certified compounds dispensed with personalised dosing protocols.
HIPAA Compliant · GMP Certified · Physician Supervised